Newsletter>
THE VALUE OF PORPHYRIN TESTING IN AUTISM

Here is an article that supports the implication of  
environmental factors, especially heavy metals, in autism 
spectrum disorders. Note that it is published in a 
conventional medical journal. 
 
Porphyrin testing is offered at my office for $115. It is 
a simple urine test which takes about 2 weeks to get 
results back. 
 
 
 
US Autism & Asperger Association, Inc. 2007  
 
 
NEWS RELEASE:For Immediate Release - October 1, 2007 
 
Urine Testing Confirms Autism is Mercury Poisoning 
 
WASHINGTON, DC – A new peer-reviewed scientific/medical 
case study confirms that many children with autistic 
spectrum disorders (ASDs) suffer from mercury poisoning. 
The new study, “A Prospective Study of Mercury Toxicity 
Biomarkers in Autistic Spectrum Disorders” by Mr. David A. 
Geier and Dr. Mark R. Geier has been published in the most 
recent issue of the Journal of Toxicology and Environmental 
Health, Part A (volume 70, issue 20, pgs 1723-1730). This 
study utilized urinary porphyrin profile analysis (UPPA) to 
assess body-burden and physiological effects of mercury in 
children diagnosed with ASDs. Using UPPA, Geier and Geier 
(2007) examined 71 children diagnosed with ASDs, 
neurotypical siblings, and general population controls. The 
researchers studied urinary porphyrin patterns using 
results reported both by the US Laboratory Corporation of 
America (LabCorp) and the French Laboratoire Philippe 
Auguste. Their findings demonstrated that: * Only the 
non-chelated patients diagnosed with ASDs had porphyrin 
patterns indicative of clinical mercury toxicity. * 
Treating ASD diagnosed patients with chelating agents 
resulted in lower mercury-specific urinary porphyrins. * 
The UPPA patterns reported were consistent between the two 
labs used. The results of the present study confirm and 
extend previous observations by Nataf et al. (2006) and 
Geier and Geier (2006) on the use of UPPA profiling to 
establish the causal role for mercury in ASDs. 
Additionally, the current findings are consistent with 
those observed by many other physicians who treat patients 
diagnosed with both ASDs and mercury toxicity. Thus, 
urinary porphyrin profile testing is being successfully 
used to: * Demonstrate the role of mercury in ASD 
populations, * Identify those children and adults who are 
mercury poisoned, and * Track mercury excretion from 
affected children undergoing treatment. For the past 
several years there has been a raging controversy as to 
whether or not mercury in medicines, especially in 
vaccines, has caused a dramatic rise in the rate of 
children diagnosed with an ASD. Many experts have insisted 
ASDs are caused by some yet-to-be-identified genetic cause. 
A paper recently published in Nature Genetics described the 
results of multi-million-dollar genetics study (which 
studied a thousand-plus families with at least two children 
diagnosed with an ASD using in-depth genetic screening). 
Tellingly, the authors reported, “None of our linkage 
results can be interpreted as 'statistically 
significant'…”(The Autism Genome Project Consortium 2007). 
With the current study's results, public health officials 
should now publicly admit what they have been saying in 
their private transcripts and memos: Mercury from 
Thimerosal-containing vaccines and other medicines has been 
a major cause of ASD cases, which, based on recent CDC 
estimates (CDC 2007), may exceed a rate of one in 100 
children. Today, any parent, physician, or healthcare 
provider can easily confirm whether a non-chelated child 
with an ASD diagnosis is mercury poisoned by having UPPA 
testing run at either laboratory. CoMeD's web site, 
http://www.Mercury-freeDrugs.org contains: * Further 
information on how to order these tests, * Full copies of 
the Nataf et al. (2006), Geier and Geier (2006), & Geier 
and Geier (2007), and * Some of the many published papers 
validating the UPPA test.Contact:CoMeD President [Rev. Lisa 
K. Sykes (Richmond, VA) 804-364-8426] CoMeD Sci. Advisor 
[Dr. King (Lake Hiawatha, NJ) 973-997-1321] Click here to 
read"A Prospective Study of Mercury Toxicity Biomarkers in 
Autistic Spectrum Disorders," David A. Geier, Institute of 
Chronic Illnesses, Silver Spring, Maryland, USA, Mark R. 
Geier, MD, PhD, Genetic Centers of America, Silver Spring, 
Maryland, USASummaryPorphyrins are derivatives formed in 
the heme synthesis pathway and porphyrins afford a measure 
of xenobiotic exposure. The steps in the heme pathway most 
vulnerable to heavy metal inhibition are uroporphyrin 
decarboxylase (UROD) and coproporphyrinogen oxidase (CPOX) 
reactions. Mercury toxicity was associated with elevations 
in urinary coproporphyrin (cP), pentacarboxyporphyrin 
(5cxP), and precoproporphyrin (prcP) (also known as 
keto-isocoproporphyrin) levels. Two cohorts of autistic 
patients in the United States and France had urine 
porphyrin levels associated with mercury toxicity. A 
prospective study of urinary porphyrin testing at LabCorp 
(United States) and the Laboratoire Philippe Auguste 
(France) involving 71 autism spectrum disorder (ASD) 
patients, neurotypical sibling controls, and general 
population controls was undertaken. ASD patients had 
significant elevations in urinary levels of cP, 5cxP, and 
prcP relative to controls, and > 50% of ASD patients had 
urinary cP levels more than 2 standard deviations above the 
mean values for neurotypical sibling controls. Significant 
reductions in urinary 5cxP and cP levels were observed in 
ASD patients following chelation. A significant correlation 
was found between urinary porphyrins measured at LabCorp 
and those measured at the Laboratoire Philippe Auguste on 
individual ASD patients. The established developmental 
neurotoxicity attributed to mercury and biochemical/genomic 
evidence for mercury susceptibility/ toxicity in ASDs 
indicates a causal role for mercury. Urinary porphyrin 
testing is clinically available, relatively inexpensive, 
and noninvasive. Porphyrins need to be routinely measured 
in ASDs to establish if mercury toxicity is a causative 
factor and to evaluate the effectiveness of chelation 
therapy.

Dr. Jennifer Reid
27530 SE Division Drive, Gresham, OR 97030 Telephone: (503)492-9427

Site designed by kwfx.com, click here for webmaster.